Atlas Trials

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients

Clinical trial NCT03053856 · UNKNOWN

Trial details

NCT number
NCT03053856
Sponsor
Samsung Medical Center
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Stage IIIA Non-small Cell Lung Cancer
Start date
2017-02-14
Primary completion
2021-05-13
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.